title: Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
abstract: The clinical criteria for the diagnosis of essential thrombocythemia (ET) according to the polycythemia vera study group (PVSG) do not distinguish between ET and thrombocythemia associated with early stage PV and prefibrotic chronic idiopathic myelofibrosis (CIMF). The clinical criteria of the PVSG for the diagnosis of polycythemia vera (PV) only detects advanced stage of PV with increased red cell mass. The bone marrow criteria of the World Health Organization (WHO) are defined by pathologists to explicitly define the pathological criteria for the diagnostic differentiation of ET, PV, and prefibrotic and fibrotic CIMF. As the clinical PVSG and the pathological WHO criteria show significant shortcomings, an updated set of European Clinical and Pathological (ECP) criteria combined with currently available biological and molecular markers are proposed to much better distinct true ET from early PV mimicking ET, to distinguish ET from thrombocythemia associated with prefibrotic CIMF, and to define the various clinical and pathological stages of PV and CIMF that has important therapeutic and prognostic implications. Comparing the finding of clustered giant abnormal megakaryocytes in a representative bone marrow as a diagnostic clue to MPD, the sensitivity for the diagnosis of MPD associated with splanchnic vein thrombosis was 63% for increased red cell mass, 52% for low serum EPO level, 72% for EEC, and 74% for splenomegaly indicating the superiority of bone marrow histopathology to detect masked early and overt MPD in this setting. The majority of PV and about half of the ET patients have spontaneous EEC, low serum EPO levels and PRV-1 over-expression and are JAK2 V617F positive. The positive predictive value for the diagnosis of PV of spontaneous growth of endogenous erythroid colonies (EEC) of peripheral blood (PB) and bone marrow (BM) cells is about 80-85% when either PB or BM EEC assays, and up to 94% when BM and PB EEC assays were performed. The diagnostic impact of low serum EPO levels (ELISA assay) in a large study of 186 patients below the normal range (<3.3 IU/l) had a sensitivity specificity and positive predictive value of 87%, 97% and 97.8%, respectively, for the diagnosis of PV. There is a significant overlap of serum EPO levels in PV versus control and controls versus SE. The specificity of a JAK2 V617F PCR test for the diagnosis of MPD is high (near 100%), but only half of ET and MF (50%) and the majority of PV (up to 97%) are JAK2 V617F positive. The use of biological markers including JAK2 V617 PCR test, serum EPO, PRV-1, EEC, leukocyte alkaline phosphatase score and peripheral blood parameters combined with bone marrow histopathology has a high sensitivity and specificity (almost 100%) to diagnose the early and overt stages of ET, PV and CIMF in JAK2 V617F positive and negative MPDs.
authors.affiliation: Department of Hematology, University Hospital Antwerp Wilrijkstraat 10, 2650 Edegem/Antwerp, Belgium. postbus@goodheartcenter.demon.nl
authors.forename: J J
authors.initials: JJ
authors.lastname: Michiels
authors.forename: Z
authors.initials: Z
authors.lastname: Bernema
authors.forename: D
authors.initials: D
authors.lastname: Van Bockstaele
authors.forename: H
authors.initials: H
authors.lastname: De Raeve
authors.forename: W
authors.initials: W
authors.lastname: Schroyens
mesh_terms: D019943:Amino Acid Substitution; D015415:Biomarkers; D001772:Blood Cell Count; D001853:Bone Marrow / Q000473:pathology; D019070:Cell Lineage; D003114:Colony-Forming Units Assay; D018450:Disease Progression; D004797:Enzyme-Linked Immunosorbent Assay; D004911:Erythrocyte Volume; D015672:Erythroid Precursor Cells / Q000473:pathology; D004921:Erythropoietin / Q000097:blood; D058851:GPI-Linked Proteins; D006801:Humans; D007519:Isoantigens / Q000097:blood; D053614:Janus Kinase 2 / Q000235:genetics; D008562:Membrane Glycoproteins / Q000097:blood; D020125:Mutation, Missense; D017354:Point Mutation; D011087:Polycythemia Vera / Q000097:blood / Q000175:diagnosis* / Q000235:genetics / Q000473:pathology; D016133:Polymerase Chain Reaction; D011237:Predictive Value of Tests; D055728:Primary Myelofibrosis / Q000097:blood / Q000175:diagnosis* / Q000235:genetics / Q000473:pathology; D011956:Receptors, Cell Surface / Q000097:blood; D012680:Sensitivity and Specificity; D013920:Thrombocythemia, Essential / Q000097:blood / Q000175:diagnosis* / Q000235:genetics / Q000473:pathology; D014944:World Health Organization
chemical_list: D015415:Biomarkers; C407242:CD177 protein, human; D058851:GPI-Linked Proteins; D007519:Isoantigens; D008562:Membrane Glycoproteins; D011956:Receptors, Cell Surface; D004921:Erythropoietin; C507924:JAK2 protein, human; D053614:Janus Kinase 2